Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treosulfan vs Clofarabine Conditioning for MDS-EB or AML Before Allogeneic HCT
NCT04994808Phase 2Terminated
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Aug 2023
- Primary completion
- Jan 2026
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of treosulfan, clofarabine in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by Fred Hutchinson Cancer Center. Started Aug 2023; status: terminated.
02
Drugs
treosulfanclofarabine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04994808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04994808.